Free Trial

DexCom (DXCM) Stock Price, News & Analysis

DexCom logo
$75.34 +0.26 (+0.35%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$74.86 -0.48 (-0.64%)
As of 08:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About DexCom Stock (NASDAQ:DXCM)

Key Stats

Today's Range
$74.54
$75.80
50-Day Range
$75.08
$89.53
52-Week Range
$57.52
$93.25
Volume
2.92 million shs
Average Volume
4.07 million shs
Market Capitalization
$29.54 billion
P/E Ratio
52.32
Dividend Yield
N/A
Price Target
$99.89
Consensus Rating
Moderate Buy

Company Overview

DexCom Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
100th Percentile Overall Score

DXCM MarketRank™: 

DexCom scored higher than 100% of companies evaluated by MarketBeat, and ranked 6th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    DexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 15 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    DexCom has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about DexCom's stock forecast and price target.
  • Earnings Growth

    Earnings for DexCom are expected to grow by 21.18% in the coming year, from $2.03 to $2.46 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of DexCom is 52.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.03.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of DexCom is 52.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 83.33.

  • Price to Earnings Growth Ratio

    DexCom has a PEG Ratio of 1.58. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    DexCom has a P/B Ratio of 14.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about DexCom's valuation and earnings.
  • Percentage of Shares Shorted

    2.17% of the float of DexCom has been sold short.
  • Short Interest Ratio / Days to Cover

    DexCom has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DexCom has recently decreased by 4.50%, indicating that investor sentiment is improving.
  • Dividend Yield

    DexCom does not currently pay a dividend.

  • Dividend Growth

    DexCom does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.17% of the float of DexCom has been sold short.
  • Short Interest Ratio / Days to Cover

    DexCom has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in DexCom has recently decreased by 4.50%, indicating that investor sentiment is improving.
  • News Sentiment

    DexCom has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.13 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for DexCom this week, compared to 25 articles on an average week.
  • Search Interest

    Only 17 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,306,131.00 in company stock.

  • Percentage Held by Insiders

    Only 0.32% of the stock of DexCom is held by insiders.

  • Percentage Held by Institutions

    97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about DexCom's insider trading history.
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DXCM Stock News Headlines

DexCom, Inc. (NASDAQ:DXCM) EVP Sells $40,145.00 in Stock
Argus Initiates Coverage of DexCom (DXCM) with a Buy Rating
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...tc pixel
Dexcom Announces Upcoming Conference Presentations
Why KDP, DXCM, and MRNA Shares are On Sale
See More Headlines

DXCM Stock Analysis - Frequently Asked Questions

DexCom's stock was trading at $77.77 at the beginning of 2025. Since then, DXCM shares have decreased by 3.1% and is now trading at $75.34.

DexCom, Inc. (NASDAQ:DXCM) issued its quarterly earnings data on Wednesday, July, 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. The business's revenue was up 15.2% on a year-over-year basis.
Read the conference call transcript
.

Shares of DexCom split before market open on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom subsidiaries include these companies: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and others.

DexCom's top institutional shareholders include Vanguard Group Inc. (12.32%), Jennison Associates LLC (2.94%), Geode Capital Management LLC (2.75%) and Sands Capital Management LLC (2.54%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Barry J Regan, Steven R Altman, Paul R Flynn, Mark G Foletta, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Nicholas Augustinos and Bridgette P Heller.
View institutional ownership trends
.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ).

Company Calendar

Last Earnings
7/30/2025
Today
9/02/2025
Next Earnings (Estimated)
10/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:DXCM
CIK
1093557
Employees
10,300
Year Founded
1999

Price Target and Rating

High Price Target
$115.00
Low Price Target
$85.00
Potential Upside/Downside
+32.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.95
Research Coverage
22 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.44
Trailing P/E Ratio
52.32
Forward P/E Ratio
37.11
P/E Growth
1.58
Net Income
$576.20 million
Net Margins
13.29%
Pretax Margin
18.23%
Return on Equity
30.41%
Return on Assets
10.08%

Debt

Debt-to-Equity Ratio
0.48
Current Ratio
1.52
Quick Ratio
1.35

Sales & Book Value

Annual Sales
$4.03 billion
Price / Sales
7.33
Cash Flow
$2.25 per share
Price / Cash Flow
33.52
Book Value
$5.38 per share
Price / Book
14.00

Miscellaneous

Outstanding Shares
392,150,000
Free Float
390,900,000
Market Cap
$29.54 billion
Optionable
Optionable
Beta
1.48

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:DXCM) was last updated on 9/2/2025 by MarketBeat.com Staff
From Our Partners